Development of an IL-4/IL-13:IL-4Rα in vitro to in vivo Translational Platform in a Model of Respiratory Disease.

Type 2 inflammation plays a central role in asthma and COPD, driven by IL-4 and IL-13 signalling through IL-4Rα. Whilst Dupilumab has paved the way, there remains a need for next generation IL-4Ra pathway targeted therapies.

In collaboration with Numerion Labs, Sygnature Discovery has established a scalable in vitro to in vivo platform to assess IL-4/IL-13:IL-4Rα pathway modulators utilising biophysical, biochemical and cellular methodologies alongside a disease-relevant mouse model. Validated with Dupilumab and the JAK inhibitor, Tofacitinib, this system enables functional screening and characterisation of new IL-Ra-targeting compounds.

👉 Download the free poster to understand how this integrated platform enables functional screening and in vivo validation of IL-4Rα pathway modulators.